The FDA database revealed that the medicine had been linked to myopathy, which is muscle weakness and damage.
(PRWEB) October 04, 2013
Zocor (simvastatin) helps control high cholesterol when combined with a healthy diet and exercise. The FDA approved this medicine in December 1991. It has also been approved in combination with drugs like Januvia (Juvisync) and Zetia (Vytorin). On March 19, 2011, the FDA warned “about an increased risk of muscle injury in patients taking the highest approved dose of the cholesterol-lowering medication, Zocor (simvastatin) 80 mg.” The FDA database revealed that the medicine had been linked to myopathy, which is muscle weakness and damage. The most serious form of this condition is called rhabdomolysis. At this stage, the body begins breaking down muscle which releases myoglobin. Myoglobin is a protein that is toxic to the kidney and it can cause kidney damage or failure (i). People who have suffered rhabdomyolysis due to taking Zocor should talk to an attorney about their rights.
Statins are used to lower cholesterol levels. In addition to using statins, many people adjust their diet and exercise routine for a healthier lifestyle. According to a study published in the August 2013 Journal of the American College of Cardiology, Zocor prevented patients from receiving the full benefit of exercise. The study followed 37 previously inactive adult participants who took the drug in combination with exercise. The researchers found that the use of Zocor “blunted” the positive effects of exercise (ii). People who have been prescribed medicine such as statins should monitor how their body responds to the drug.
The Zocor infographic provides information on the risks associated with the drug especially when taken at high doses. d’Oliveira & Associates focuses exclusively on personal injury lawsuits and disability claims. The law firm works with some of the more experienced Zocor lawyers and there are no legal fees unless a settlement or award is obtained. To contact the firm call toll-free at 1-800-992-6878 or submit an online contact form.
(i) FDA Drug Safety Communication, March 2010.
(ii) Journal of the American College of Cardiology, August 2013.